Dr Barry Buckland joines the Mucosis Supervisory Board

Dutch biotech­nol­o­gy com­pa­ny Mucosis B.V. announced today that Dr. Barry Buckland was elect­ed to its Supervisory Board. Dr Buckland brings exten­sive expe­ri­ence in vac­cine design and devel­op­ment.

From 1996 to 2009, Dr. Buckland was Vice President, BioProcess R&D at Merck & Co, Inc. He built the unit and was respon­si­ble for process devel­op­ment for 14 new com­mer­cial prod­ucts, includ­ing 10 new vac­cines. More recent­ly Dr Buckland has been a con­sul­tant to Hilleman Laboratories, the vac­cine ven­ture estab­lished between Merck and The Wellcome Trust. Dr Buckland received many pro­fes­sion­al and aca­d­e­m­ic hon­ors, includ­ing the 2008 Marvin Johnson Award from the American Chemical Society for life­time con­tri­bu­tion to biotech­nol­o­gy. He has authored 77 sci­en­tif­ic papers.

“I am delight­ed to have this oppor­tu­ni­ty to con­tribute to the suc­cess of Mucosis” com­ment­ed  Dr. Buckland. “The Company’s mucos­al immu­ni­ty plat­form will have many appli­ca­tions in devel­op­ing supe­ri­or vac­cines”.

John Lambert, Chairman of Mucosis added: “Barry’s insight and expe­ri­ence stem from being involved in the design, devel­op­ment and com­mer­cial­iza­tion of many of today’s block­buster vac­cines. He will be invalu­able to Mucosis”.

Leave a Reply

Your email address will not be published. Required fields are marked *